Full Text
Are Pharmaceutical Companies Prioritizing Multi-Indication Drugs?

Abstract

Authors

BF Lurie J Rubinstein ER Rubinstein SB Rosenblum Y Ho

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×